Karn Vamika, Sandhya Sandhya, Hsu Wayne, Parashar Deepak, Singh Himanshu Narayan, Jha Niraj Kumar, Gupta Saurabh, Dubey Navneet Kumar, Kumar Sanjay
Department of Biotechnology, Amity University, Mumbai, 410221, India.
Division of Oncology Research, Mayo Clinic, Rochester, MN, 55905, USA.
Cancer Cell Int. 2022 Jul 25;22(1):234. doi: 10.1186/s12935-022-02654-3.
Cancer is one of the major causes of mortality worldwide, therefore it is considered a major health concern. Breast cancer is the most frequent type of cancer which affects women on a global scale. Various current treatment strategies have been implicated for breast cancer therapy that includes surgical removal, radiation therapy, hormonal therapy, chemotherapy, and targeted biological therapy. However, constant effort is being made to introduce novel therapies with minimal toxicity. Gene therapy is one of the promising tools, to rectify defective genes and cure various cancers. In recent years, a novel genome engineering technology, namely the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9) has emerged as a gene-editing tool and transformed genome-editing techniques in a wide range of biological domains including human cancer research and gene therapy. This could be attributed to its versatile characteristics such as high specificity, precision, time-saving and cost-effective methodologies with minimal risk. In the present review, we highlight the role of CRISPR/Cas9 as a targeted therapy to tackle drug resistance, improve immunotherapy for breast cancer.
癌症是全球主要的死亡原因之一，因此它被视为一个重大的健康问题。乳腺癌是全球范围内影响女性的最常见癌症类型。目前有多种治疗策略用于乳腺癌治疗，包括手术切除、放射治疗、激素治疗、化疗和靶向生物治疗。然而，人们一直在不断努力推出毒性最小的新型疗法。基因治疗是纠正缺陷基因和治愈各种癌症的有前景的工具之一。近年来，一种新型的基因组工程技术，即成簇规律间隔短回文重复序列（CRISPR）相关蛋白9（Cas9），已作为一种基因编辑工具出现，并在包括人类癌症研究和基因治疗在内的广泛生物领域中改变了基因组编辑技术。这可归因于其通用特性，如高特异性、精确性、省时且具有成本效益的方法以及最小风险。在本综述中，我们强调CRISPR/Cas9作为一种靶向疗法在应对耐药性、改善乳腺癌免疫治疗方面的作用。
